Elena Christofides, MD, FACE
Basic profileEndocrinology, Diabetes & Metabolism
Elena Christofides is an Endocrinology/Metabolic physician. OpenAlex indexes 30 publications with 620 citations (h-index 7); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Sponsor: Gan and Lee Pharmaceuticals, USA
- Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
Sponsor: Gan and Lee Pharmaceuticals, USA
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
61 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli LillyProgram year20252 paymentsResearch$152,535
- RECORDATI_RARE_DISEASES_INC.Program year2025107 payments$92,277
- Corcept TherapeuticsProgram year202595 payments$90,271
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
43.7%GLP-1 receptor agonist14.7%Mounjaro37%Ozempic37%Trulicity26%Part D≥12 patientsThiazolidinedione11.7%Pioglitazone Hcl89%Pioglitazone-Metformin11%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
23%l-Thyroxine14.1%Synthroid100%Part D≥47 patientsRecombinant Human Growth Hormone4%Genotropin59%Omnitrope41%Part D<11 patients+ 2 more classes in this area
Cardiovascular
18.4%Statin5.2%Atorvastatin Calcium100%Part D≥20 patientsOmega-3 / fibrate3.8%Omega-3 Acid Ethyl Esters100%Part D≥13 patients+ 7 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”